KS HB2218

Excludes crystalline polymorph psilocybin (known as COMP 360) from the definition of "psilocybin" in the Uniform Controlled Substances Act when approved by the FDA as a pharmaceutical composition

Adds FDA-approved crystalline polymorph psilocybin to Schedule IV controlled substances, allowing it to be prescribed with lower restrictions than Schedule I substances like standard psilocybin

Requires the Attorney General to certify FDA approval of the drug to the Secretary of State within seven days of approval, with publication in the Kansas Register

Provisions take effect only upon FDA approval and subsequent publication of certification in the Kansas Register, making the law contingent on federal regulatory action

Requested by Compass Pathways, the pharmaceutical company developing COMP 360 for treatment-resistant depression